Last reviewed · How we verify

NCT06354790: LAMA2

Natural History Study of Children With LAMA2-related Dystrophies

Recruiting now Last updated 12 December 2024
What this trial tests

trial testing Motor evaluations in Merosin Deficient Congenital Muscular Dystrophy in 40 participants. Currently enrolling.

Timeline
5 December 2024
Primary endpoint
4 December 2027
31 December 2027

Quick facts

Lead sponsorInstitut de Myologie, France
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date5 December 2024
Primary completion4 December 2027
Estimated completion31 December 2027
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Institut de Myologie, France — full company profile →

Who can join

Adults 2 to 15, any sex, with Merosin Deficient Congenital Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this natural history study is to characterize the disease course, characteristics in paediatric population of LAMA2-RD (related dystrophies) patients. The aim of the study is to establish a well-described cohort of patients in France with LAMA2-RD for prospective follow-up and recruitment for future clinical trials. Participants will be follow up during a two years period regarding exhaustive aspects of the pathology: * Muscular function * Respiratory function * Cognitive phenotyping * Quality of life * Growth parameters * Biomarkers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Merosin Deficient Congenital Muscular Dystrophy

Currently open trials in the same condition.

Other Institut de Myologie, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06354790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing